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Abstract
Introduction To evaluate the long-term outcome of image-
guided radiofrequency ablation (RFA) when treating his-
tologically confirmed colorectal lung metastasis in terms of
overall survival (OS), progression-free survival (PFS) and
local tumour control (LTC).
Materials and Methods Retrospective single-centre study.
Consecutive RFA treatments of histologically proven lung
colorectal metastases between 01/01/2008 and 31/12/14. The
primary outcome was patient survival (OS and PFS). Sec-
ondary outcomes were local tumour progression (LTP) and
complications. Prognostic factors associated with OS/ PFS
were determined by univariate and multivariate analyses.
Results Sixty patients (39 males: 21 females; median age
69 years) and 125 colorectal lung metastases were treated.
Eighty percent (n = 48) also underwent lung surgery for
lung metastases. Mean metastasis size (cm) was 1.4 ± 0.6
(range 0.3–4.0). Median number of RFA sessions was 1
(1–4). During follow-up (median 45.5 months), 45 patients
died (75%). The estimated OS and PFS survival rates at 1,
3, 5, 7, 9 years were 96.7%, 74.7%, 44.1%, 27.5%, 16.3%
(median OS, 52 months) and 66.7%, 31.2%, 25.9%, 21.2%
and 5.9% (median PFS, 19 months). The LTC rate was
90% with 6 patients developing LTP with 1-, 2-, 3- and
4-year LTP rates of 3.3%, 8.3%, 10.0% and 10.0%. Pro-
gression-free interval\ 1 year (P = 0.002, HR = 0.375)
and total number of pulmonary metastases (C 3) treated
(P = 0.037, HR = 0.480) were independent negative
prognostic factors. Thirty-day mortality rate was 0% with
no intra-procedural deaths.Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s00270-020-02623-1) contains sup-
plementary material, which is available to authorized users.
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Conclusion The long-term OS and PFS following RFA for
the treatment of histologically confirmed colorectal lung
metastases demonstrate comparable oncological durability
to surgery.
Keywords Radiofrequency ablation  Colorectal 
Metastases  Lung  Overall survival  Progression-
free survival
Introduction
Colorectal cancer is the second most common cause of
cancer death worldwide [1]. A quarter of colorectal patients
who undergo curative resection will develop distant
metastases with the lung being the second most common
site [2]. A large epidemiological study of colorectal cancer
patients with lung metastases found 3- and 5-year survival
rates of 1.3% and 6.9%, highlighting the poor prognosis in
this cohort of patients if left untreated [3]. When the
metastatic disease is localised to two or less visceral sites
(oligometastatic disease), a potentially curative approach
exists. Localised resection of lung metastases is the widely
recognised standard of care for patients with oligometa-
static disease from colorectal cancer despite the lack of
randomised control trial (RCT) data comparing treatment
options [4].
Percutaneous image-guided thermal ablation with
radiofrequency ablation (RFA) has been widely used in the
last decade and is established as a potential alternative to
surgical resection [5, 6]. It is the most suitable for patients
with small (\ 2 cm) lung metastases and in those who may
not be a surgical candidate due to their comorbidities [5, 7].
RFA of lung metastases offers a minimally invasive,
repeatable treatment, with better preservation of lung
function treatment when compared to surgical resection
[8]. No studies directly compare RFA with surgery, but
published results suggest local control and survival rates
similar to surgery [8, 9]. Long-term survival data on RFA
remain limited when compared to the surgical literature,
making it difficult to draw definitive conclusions on the
long-term oncological durability of the treatment [10].
The aim of this study was to report the long-term sur-
vival outcomes of image-guided RFA when treating his-
tologically confirmed colorectal lung metastasis in terms of
overall survival (OS), progression-free survival (PFS) and
local tumour control (LTC).
Methods
Study Population
The study involved retrospective analysis of a prospec-
tively collected database. It was performed under a waiver
of informed consent and ethics approval by the institutional
review board.
All consecutive image-guided pulmonary RFA proce-
dures undertaken between 1 January 2008 and 31
December 2014 were reviewed. Inclusion criteria were
treatment for oligometastatic colorectal metastases with
histological confirmation either from surgical resection or
percutaneous image-guided biopsy at the time of or prior to
ablation of at least one lung lesion. Patients without his-
tological confirmation and those with other primary
pathologies were excluded from this study.
All treatments were performed in a single regional ter-
tiary cancer centre. The lung metastases treatment deci-
sions were made by the local multidisciplinary team
(MDT) which included thoracic surgery and interventional
oncology. Treatment decisions were made on the basis of
the likelihood of technical success, preservation of lung
function, the requirement to obtain histological confirma-
tion of disease, the performance status of the patient and
the patient’s choice. At the time of the study, stereotactic
radiotherapy (SABR) had not been commissioned for the
treatment of lung metastases.
RFA Procedure and Follow-up
All treatments were targeted with computed tomography
(CT) guidance and performed under general anaesthesia
(GA). The RFA device utilised a unipolar multi-tined
expandable applicator that delivered alternating RF current
controlled by the impedance in the RF treatment algorithm
(LeVeen; Boston Scientific, Natick, MA).
The aim of treatment was to ablate the lung metastasis
with a minimum of a 5-mm treatment margin. Lesions in
the same lung were treated in a single session, but con-
tralateral lesions were treated at a different treatment ses-
sion due to the risk of pneumothorax. An immediate post-
RFA unenhanced chest CT was obtained after RFA elec-
trode removal to assess for pneumothorax. All pneumoth-
oraces were observed for up to 10 min under GA, and
enlargement was considered an indication for drainage. All
patients were observed overnight following RFA for
potential complications, and a chest radiograph was per-
formed 4 h post-RFA and before discharge to ensure there
was no delayed or worsening pneumothorax.
An unenhanced chest CT scan was performed at 1, 3, 6,
12, 18, 24 months and then yearly after the RFA to
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evaluate the local control rate, the presence of new meta-
static disease within the lungs and for any complications.
All patients with local tumour progression were reassessed
by consensus of the local MDT for suitability of surgical
resection or repeat image-guided thermal ablation
eligibility.
Definitions of Study Outcome Measures
Standardised definitions of outcomes and grading of com-
plications were applied [5, 11, 12].
Technical success of RFA was defined as the complete
coverage of the tumour by the ablation zone of ground
glass opacity (GGO), with at least a 5-mm ablative treat-
ment margin seen on the CT imaging at the end of the
procedure. GGO was defined as increased opacification of
lung, with preservation of bronchial and vascular margins
as per the Fleischner Society [13]. Technical failure was
defined as incomplete tumour ablation with the presence of
residual tumour at the end of the RFA treatment session not
encompassed within the ablation zone or with less than
5-mm ablative treatment margin.
Local tumour progression (LTP) was defined by the
appearance of tumour foci inside or at the edge of the
ablation zone during imaging follow-up, provided that
complete ablation with adequate margins could be docu-
mented with a previous study.
Time to progression (TTP) is the time interval between
first RFA and local or distant disease progression. Its
associated metric is progression-free survival (PFS) defined
as the interval from RFA to local or distant disease pro-
gression or death (from any cause); both are measures of
oncologic efficacy rather than technical success. Overall
survival (OS) was defined as the time from first treatment
with RFA to death (from any cause). RFA-related adverse
events were assessed according to the CIRSE classification
system [12].
Statistical Analysis
Statistical analyses were performed using SPSS software
(version 23.0; IBM Corp, Armonk, New York). Kaplan–
Meier method used to evaluate OS and PFS with 95%
confidence intervals (CI) was calculated. To detect prog-
nostic factors the following variables were collected: sex
(male or female), progression-free interval (\ 1 year or
C 1 year), history of lung surgery for metastases (yes or
no), total number of pulmonary metastases treated by RFA
and surgery (\ 3 or C 3), largest size of ablated tumour
(\ 2 cm or C 2 cm), history of liver metastases (yes or no)
and chemotherapy prior to RFA (yes or no) (Supplemen-
tary material). Univariate analyses were performed by the
log-rank test to compare the survival rates (for both OS and
PFS) between each pair of groups/prognostic factors
(Supplementary material). Multivariate analyses to deter-
mine the independent prognostic factors were performed
using the Cox proportional-hazards model. For all analyses,
a P value of \ 0.05 was considered statistically
significant.
Results
A total of 96 patients underwent RFA between 1 January
2008 and 31 December 2014. In total, 60 patients with
histologically confirmed colorectal lung metastases
(n = 125) treated by image-guided RFA were included in
the retrospective analysis. Patient characteristics are dis-
played in Table 1. The 36 patients excluded were due to
lack of histological confirmation of colorectal metastases
or treatment for other disease pathologies. The mean
metastasis size was 1.4 cm. Standard deviation (SD) was
0.6 cm and ranges 0.3–4.0 cm.
The median duration of follow-up after the initial
image-guided RFA was 45.5 months (range 3–141).
Out of the 28 patients who had a history of colorectal
liver metastases (Table 1), 27 had locoregional liver
treatment with either liver ablation or resection for their
colorectal metastases.
The maximum number of lung metastases treated with
image-guided RFA was 9, and this patient had two separate
treatment sessions to treat left lower lobe nodules (n = 5)
followed by a further treatment session to treat the left
upper lobe nodules (n = 4).
Local Tumour Progression and Long-Term Survival
Outcomes
Out of 125 treated pulmonary metastases, the primary
technical success rate in this cohort was 99.2%. One patient
had incomplete treatment of a metastasis (technical failure)
and required a second RFA to successfully treat the
residual disease. The overall technical success rate for this
cohort of patients treated with image-guided RFA for their
colorectal lung metastasis was 100%
The overall LTC rate was 90% with 10% of the patients
(n = 6) developing LTP with a median time to local pro-
gression of 18 months (range 10–26) from the initial
treatment. The LTP rate was 3.3% at 1 year, 8.3% at
2 years, 10.0% at 3 years and 10.0% at 4 years.
During the study review period (01/01/2008–31/12/
2019), a total of 45 patients with colorectal lung metastasis
treated with image-guided RFA (75%) died. The causes
were disease progression (n = 29), heart failure (n = 2),
decompensated liver disease (n = 1) or unknown causes
(n = 13).
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The Kaplan–Meier survival analysis for all patients
(n = 60) found the median OS to be 52 months (95% CI
39.3–64.7) (Fig. 1). The 1-, 3-, 5-, 7- and 9-year overall
survival rates were 96.7%, 74.7%, 44.1%, 27.5 and 16.3%.
Median PFS was 19 months (95% CI 9.6–28.4) (Fig. 2).
The 1-, 3-, 5-, 7- and 9-year progression-free survival rates
were 66.7%, 31.2%, 25.9%, 21.2% and 5.9%.
Univariate and multivariate analysis (detailed break-
down provided for each prognostic factor is provided in
Supplementary Information) identified progression-free
interval of less than one year to be significantly associated
with worse OS (P = 0.002, hazard ratio 0.375), and the
total number of pulmonary metastases (C 3) treated was
significantly associated with worse PFS (P = 0.037, hazard
ratio 0.480).
Adverse Events
For this patient cohort, the 30-day post-RFA mortality rate
was 0% with no intra-procedural deaths.
In total, 36 patients (60%) developed a pneumothorax
(Grade 1) following RFA, and all were diagnosed on the
immediate postprocedural unenhanced chest CT. Of these
patients, 18 required a CT-guided chest drain insertion to
relieve the enlarging pneumothorax, while the remainder
were managed conservatively with spontaneous resolution.
Two (3%) patients required a chest drain for a subsequent
reactive effusion (Grade 2). Two patients (3%) developed a
post-RFA air leak requiring video-assisted thoracoscopic
surgery (Grade 3).
Table 1 Patient characteristics
Characteristic Value (%/ range)
Age (y)
Median 69 (31–89)
Sex
Male 39 (65%)
Female 21 (35%)
Site of primary cancer
Colon 28 (46.7%)
Sigmoid 5 (8.3%)
Rectum 27 (45%)
History of lung surgery for metastases
Yes 48 (80%)
No 12 (20%)
Chemotherapy prior to RFA
Yes 21 (35%)
No 39 (65%)
History of colorectal liver metastases
Yes 28 (47%)
No 32 (53%)
Number of lesions treated with RFA Total = 125
Median 2 (1–9)
Number of lesions treated with surgery Total = 143
Median 2 (1–10)
Number of RFA sessions Total = 82
Median 1 (1–4)
Maximum size of ablated tumour
0–1 cm 71 (57%)
1–2 cm 48 (38%)
2–3 cm 5 (4%)
3–4 cm 1 (1%)
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Fig. 1 Graph shows Kaplan–Meier overall survival estimate for all
patients with metastasis to lung from colorectal carcinoma treated
with RFA. Dotted lines represent 95% confidence intervals
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Fig. 2 Graph shows Kaplan–Meier progression-free survival estimate
for all patients with metastasis to lung from colorectal carcinoma
treated with RFA. Dotted lines represent 95% confidence intervals
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Discussion
A median overall survival of 52 months with a five-year
OS and PFS of 44.1% and 25.9%, respectively, is in line
with existing literature. Few previous studies have exam-
ined long-term survival following RFA in colorectal
metastases (Table 2) [14–18], and none included only
patients with histological confirmation as in the current
study. Although desirable, histological confirmation is not
always feasible prior to treatment. A relevant clinical his-
tory with concordant imaging may sufficiently support an
MDT decision to proceed with treatment. Biopsy at the
time of ablation risks inducing haemorrhage or pneu-
mothorax and may jeopardise accuracy of RF probe
placement. One recently suggested option to mitigate these
risks is to biopsy immediately after RFA which carries a
diagnostic sampling rate of 90% [19].
The results of this current study support the findings of
previous studies without comprehensive histological con-
firmation. A systematic review by Lyons et al. [20] inclu-
ded over 900 patients from 8 RFA studies on colorectal
lung metastases and demonstrated OS rates at 5 years of
19.9% and PFS rates of 7%. A more recent study by Matsui
et al. published a more favourable 5-year OS rate of 52%
with a median OS of 67 months [15]. Differences in the
outcomes data can reflect confounders within the different
patient populations. The improved long-term survival
observed in more recent studies is possibly attributable to
advancement in chemotherapy for metastatic colorectal
cancer in the neoadjuvant and palliative setting [21].
The LTC rate in this study was 90% and a median time
to LTP of 18 months (3–26). This is consistent with other
studies which quote a LTC rate of 69–87% [15, 22, 23].
The median time to LTP in the published RFA literature is
variable [10]. Previous studies have quoted the median
times to LTP in the range of 8.2–11.2 months; however,
the ranges vary widely from 2.6 to 43.7 months [15, 23]. In
the largest published RFA series by de Baère et al. [7], the
1-, 2-, 3- and 4-year local tumour progression (LTP) rates
were 5.9%. 8.5%, 10.2% and 11%, respectively. Our study
confirms the finding that the majority of local recurrences
occur within the first 2 years following treatment.
In terms of prognostic factors, this study confirms that
the total number of pulmonary metastases (C 3) treated
with RFA and surgery is associated with worse PFS
(P = 0.037). The number of metastases has also been found
to a predictor of survival in other large retrospective RFA
studies [7] and surgical series [24]. The current study
confirmed a previously demonstrated lack of correlation
between a history of treated liver metastases with survival
[17, 23].
Surgical series (Table 3) have shown favourable long-
term survival rates, and despite the absence of RCT data,
resection is considered first-line treatment [4]. Surgical
literature focuses on 5-year survival with estimates ranging
between 38.3 and 71.3% [24–33]. The ablation literature
frequently quotes 1–3-year survival, but when reported the
five-year survival after thermal ablation is less favourable
compared to the surgical literature and the 5-year survival
rates following RFA ranges between 19.9 and 57%
[7, 14, 15, 34–36]. A multi-centre surgical series [33]
found 5-year disease-free and OS rates of 37.1% and 68.1%
(compared to 30.4% and 44.1% in the current study), over a
median follow-up of 65 months. The favourable survival
rates may be partly attributable to patient selection criteria
with a higher proportion (75%) of patients with a solitary
metastasis and only complete resections included in the
results [33, 37]. Comparing ablation with surgical out-
comes fails to recognize that these are frequently not
mutually exclusive groups. Eighty percent of the patients in
our study also had surgical resection for colorectal lung
metastases. This is higher than other published cohorts,
which varies from 45 to 53% [15, 23]. This is perhaps a
reflection of a collaborative MDT approach where
Table 2 RFA studies of colorectal lung metastases reporting 5-year survival data
Authors Year Number of patients Ablation modality Overall survival rates (%) Mean/median survival (months)
1 y 3 y 5 y
Simon et al. [34] 2007 18 RFA 87 57 57 –
Yamakado et al. [45] 2009 78 RFA 84 56 35 38
Matsui et al. [15] 2015 84 RFA 95.2 65 51.6 67
Ferguson et al. [35] 2015 157 RFA 89 44 19.9 33.3
de Baère et al. [7] 2015 566* RFA 92.4 67.7 51.5 62
Vogl et al. [22] 2016 41 RFA 76.9 50.8
(2 y)
8
(4 y)
24.2
Shi et al. [36] 2017 43* RFA 77 42 34 –
The asterisk (*) highlights inclusion of non-colorectal lung metastases
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complete treatment of the lung metastases with preserva-
tion of lung function regardless of underlying fitness is one
of the stated aims. Image-guided thermal ablation of lung
metastases in our cancer centre acts as an adjunct rather
than competitor to the existing surgical resection cancer
service in this cohort of patients.
Although microwave ablation (MWA) has theoretical
advantages over RFA, such as less heat sink effect and
potentially more uniform ablation zones in a shorter time
[22, 38–40], the LUMIRA RCT has found no statistically
significant difference between MWA and RFA in terms of
survival [41]. In 2019, a meta-analysis of 53 studies
showed the 5-year OS rates for RFA-treated patients
(n = 738) were higher compared with MWA-treated
patients (n = 469) (P\ 0.001) and treatment with RFA
was correlated with a longer median OS of 34.8 months
compared to 18.7 for MWA [6]. Confounding factors may
be that RFA is better known and has been used for longer,
with more reproducible results, whereas MWA is a newer
modality with smaller study sample sizes. Larger groups
with longer follow-up periods are required before firm
conclusions can be drawn.
Currently, no RCT exists that compares thoracic surgery
versus image-guided ablation and will be difficult to
achieve. The recent Pulmonary Metastasectomy in
Colorectal Cancer (PulMiCC) trial (comparing surgery vs
active monitoring) had to be stopped due to failure to
recruit the required number of patients [44]. An RCT in the
setting of colorectal lung metastases would also be of
questionable value, given many patients receive multiple
different treatment modalities throughout their course.
Registries can provide evidence of the technical success
and safety of ablation in the context of treating metastatic
disease.
The limitations of this study were the retrospective
single-centre design with a small sample size. Given that
only patients with histological proven cancer were inclu-
ded, this may have biased the results towards better out-
comes if comorbid patients were not subjected to biopsy
due to the inherent small additional risks of lung biopsy.
Conclusion
The long-term OS and PFS following RFA for the treat-
ment of histologically confirmed colorectal lung metastases
demonstrate comparable oncological durability to surgery.
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Table 3 Surgical studies focusing on colorectal lung metastases with reported 5-year survival data
Authors Year Number of patients Overall survival rates (%) Mean/median survival (months)
1 y 3 y 5 y
Kanemitsu et al. [25] 2004 313 90.4 53.0 38.3 38.4
Yedibela et al. [26] 2006 153 – 64
(2 y)
37 39
Welter et al. [27] 2007 169 – – 39 47.2
Onaitis et al. [28] 2009 378 – 78 56 –
Blackmon et al. [24] 2012 229 – – 55.4 70.1
Iida et al. [29] 2013 1030 – – 53.5 69.5
Hirosawa et al. [30] 2013 266 – – 56.5 –
Bolukbas et al. [31] 2014 165 – – 54 64
Sun et al. [32] 2017 154 – – 71.3 –
Okumura et al. [33] 2017 785 – – 68.1 –
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